

Diabetic foot ulcer - Pipeline Insight, 2021

<https://marketpublishers.com/r/DFED3B7E8F0EN.html>

Date: June 2021

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: DFED3B7E8F0EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Diabetic foot ulcer - Pipeline Insight, 2021," report provides comprehensive insights about 34+ companies and 34+ pipeline drugs in Diabetic foot ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Diabetic foot ulcer Understanding

Diabetic foot ulcer: Overview

A diabetic foot ulcer is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of diabetic foot ulcers requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and

correction of peripheral arterial insufficiency.

'Diabetic foot ulcer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic foot ulcer pipeline landscape is provided which includes the disease overview and Diabetic foot ulcer treatment guidelines. The assessment part of the report embraces, in depth Diabetic foot ulcer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic foot ulcer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic foot ulcer R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic foot ulcer.

Diabetic foot ulcer Emerging Drugs Chapters

This segment of the Diabetic foot ulcer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic foot ulcer Emerging Drugs

Galnobax: NovaLead Pharma

Galnobax is a topical gel for non-healing chronic wounds. It is a repurposed generic drug molecule, which is in Phase III clinical studies for the treatment of diabetic foot ulcer (DFU).

Nemonoxacin: TaiGen Biotechnology

Nemonoxacin is a non-fluorinated quinolone (NFQ) based bacterial topoisomerase inhibitor. The drug is in Phase II clinical developmental studies for the treatment of Diabetic foot ulcer. The drug is approved for the treatment of community-acquired pneumonia.

Further product details are provided in the report..

Diabetic foot ulcer: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic foot ulcer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetic foot ulcer

There are approx. 34+ key companies which are developing the therapies for Diabetic foot ulcer. The companies which have their Diabetic foot ulcer drug candidates in the most advanced stage, i.e. Phase II include, NovaLead Pharma.

Phases

DelveInsight's report covers around 34+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Diabetic foot ulcer pipeline report provides the therapeutic assessment of the pipeline

drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic foot ulcer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic foot ulcer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic foot ulcer drugs.

Diabetic foot ulcer Report Insights

Diabetic foot ulcer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Diabetic foot ulcer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Diabetic foot ulcer drugs?

How many Diabetic foot ulcer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic foot ulcer?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic foot ulcer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Diabetic foot ulcer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

NovaLead Pharma

Helixmith

ShangHai HaiHe Pharmaceutical

Beyond Air

TaiGen Biotechnology

RHEACELL

Technophage

Transwell Biotech

Roche

Chiesi Farmaceutici

Blue Blood Biotech

Cynata Therapeutics

ZZ Biotech

APstem Therapeutics

Lewis and Clark Pharmaceuticals

Destiny Pharma

SCM Lifescience

Key Products

Galnobax

VM-202

ON101

Nitric oxide

APZ2

Nemonoxacin

TP-102

TWB-103

Efmarodocokin alfa

CHF-6467

BB 101

Cymerus MSC

3K3A-APC

AP Skin 01

LNC-001 therapeutics

XF-70

Mesenchymal stem cell therapy

Contents

Introduction

Executive Summary

Diabetic foot ulcer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Diabetic foot ulcer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Diabetic foot ulcer companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Diabetic foot ulcer Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Galnobax: NovaLead Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

Nemonoxacin: TaiGen Biotechnology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)

Comparative Analysis

CHF-6467: Chiesi Farmaceutici

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Preclinical/Discovery Stage Products

Comparative Analysis

AP Skin 01: APstem Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Diabetic foot ulcer Key Companies

Diabetic foot ulcer Key Products

Diabetic foot ulcer- Unmet Needs

Diabetic foot ulcer- Market Drivers and Barriers

Diabetic foot ulcer- Future Perspectives and Conclusion

Diabetic foot ulcer Analyst Views

Diabetic foot ulcer Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Diabetic foot ulcer
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Diabetic foot ulcer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Diabetic foot ulcer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/DFED3B7E8F0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DFED3B7E8F0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970